Protalix BioTherapeutics Profile

USD 0.003  0.49%
0.61Last Month High 0.73 
0.61Trading Day  High 0.62 

Protalix BioTherapeutics Summary

Protalix BioTherapeutics Inc (PLX) is traded on American Stock Exchange in USA. It is located in ISRAEL and employs 223 people. Protalix BioTherapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with total capitalization of 85.65 M. Protalix BioTherapeutics Inc has 139.73 M outstanding shares of which 0 shares are at this time shorted by investors with about 0.0 days to cover shorted positions. PROTALIX BIOTHERA has about 33.48 M in cash with (34.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24.
Check Protalix BioTherapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Highbridge Capital Management LlcDebt7.5 M6.3 M
Highbridge Capital Management LlcCommon Shares4.6 M2.7 M
Renaissance Technologies LlcCommon Shares2.1 M1.2 M
Susquehanna International Group LlpCall Options192.5 K112 K
View Protalix BioTherapeutics Diagnostics

Selected Protalix BioTherapeutics Inc Income Statement Over Time

Net Income    Revenues    

Key Fundamentals

Protalix BioTherapeutics Against Markets

Current Ratings  

Protalix BioTherapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
< 47% 
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameProtalix BioTherapeutics Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
Business Address2 Snunit Street, Science Park, POB 455, Carmiel 20100, Israel
Foreign Associate  Israel
ExchangeAmerican Stock Exchange
CIK Number01006281.0
IndustryPharmaceutical Products
Contact Number(972) 4 988 9488
CurrencyUSD - US Dollar


Protalix BioTherapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
2.6Strong Buy2Odds
Protalix BioTherapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Protalix BioTherapeutics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Protalix BioTherapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.11March 14, 2017
Protalix BioTherapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate